Manufacture of immunoglobulin products for patients with primary antibody deficiencies  - the effect of processing conditions on product safety and efficacy by Farrugia, Albert & Quinti, Isabella
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 23 December 2014
doi: 10.3389/fimmu.2014.00665
Manufacture of immunoglobulin products for patients with
primary antibody deficiencies – the effect of processing
conditions on product safety and efficacy
Albert Farrugia1,2,3* and Isabella Quinti 4
1 Faculty of Medicine and Surgery, Department of Surgery, Centre for Orthopaedic Research, University ofWestern Australia, Perth,WA, Australia
2 College of Medicine, Biology and Environment, Australian National University, Acton, ACT, Australia
3 Plasma Protein Therapeutics Association, Annapolis, MD, USA
4 Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
Edited by:
Anna Villa, National Council of
Research (CNR), Italy
Reviewed by:
Elham Hossny, Ain Shams University,
Egypt
Mark Ballow, State University of New
York at Buffalo, USA
*Correspondence:
Albert Farrugia, Perth, Australia
e-mail: albert.farrugia@uwa.edu.au
Early preparations of immunoglobulin (Ig) manufactured from human plasma by ethanol
(Cohn) fractionation were limited in their usefulness for substitution therapy in patients
with primary antibody deficiencies (PAD), as Ig aggregates formed during manufacture
resulted in severe systemic reactions in patients when given intravenously. Developments
in manufacturing technology obviated this problem through the capacity to produce con-
centrated solutions of intact monomeric Ig, revolutionizing PAD treatment and improving
patient life expectancy and quality of life. As the need for Ig has grown, manufacturers have
refined further manufacturing technologies to improve yield from plasma and produce ther-
apies, which are easier and less expensive to deliver.This has led to the substitution, partly
or wholly, of ethanol precipitation by other techniques such as chromatography, and has
also stimulated the production of highly concentrated solutions capable of rapid infusion. Ig
products have been associated, since their inception, with certain adverse events, includ-
ing infectious disease transmission, hemolysis, and thromboembolism. The introduction
of standardized manufacturing processes and dedicated pathogen elimination steps has
removed the risk of infectious disease, and the focus of attention has shifted to other
problems, which appear to have increased over the past 5 years. These include hemolysis
and thromboembolism, both the cause for substantial concern and the subject of recent
regulatory scrutiny and actions. We review the development of manufacturing technology
and the emerging evidence that changes for the optimization of yield and convenience has
contributed to the recent incidents in certain adverse events. Industry measures under
development will be discussed in terms of their potential to improve safety and optimize
care for patients with PAD.
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INTRODUCTION
DEVELOPMENT OF MANUFACTURING METHODS FOR THERAPEUTIC
IMMUNOGLOBULIN PREPARATIONS
Immunoglobulins (Igs) may claim to be, historically, the first
therapeutic plasma product, with Emil von Behring’s work on
diphtheria antitoxin and von Behring and Kitasato’s demonstra-
tion (1) that serum of rabbits immunized with tetanus toxin
contained activity against experimentally induced tetanus poison,
which provided protection to non-immunized rabbits exposed to
tetanus. For this work, von Behring was awarded the first Nobel
Prize in Medicine or Physiology in 1901. Ehrlich (2) demon-
strated that protection was correlated with the amount of anti-
toxin administered. Antibody preparations such as these, where
protective antitoxin is generated through the immunization of
animals, still have a role in the treatment of some conditions
(3). Karelitz’s work showing that protection against measles was
localized to the globulin portion of serum (4) and Tiselius’ char-
acterization of serum proteins using electrophoresis (5) pointed
to the role of gamma globulin in passive immunity. However,
the manufacture of Ig solutions from a human source had to
await Cohn’s development of methods to separate plasma frac-
tions on a large scale (6), using ethanol as a precipitating agent
in a series of separations manipulating pH, ionic strength, and
temperature. Initial clinical experience with the immune serum
globulin (ISG) fraction from Cohn’s scheme quickly led to limit-
ing administration to the intramuscular and subcutaneous routes,
as severe systemic reactions occurred in patients given this product
intravenously.
Initially, ISG manufactured with Cohn’s method was limited to
prophylaxis of certain microbial diseases, including polymyelitis,
measles, mumps, pertussis, and hepatitis A (7). These prepara-
tions became redundant with the development of vaccines for the
respective diseases. In 1952, Bruton (8) infused a child with unde-
tectable “gamma globulin” levels and who suffered from chronic
infections. Subcutaneous injections of ISG produced measurable
gamma globulin levels and completely eliminated pneumococcal
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infections. Over the 1950s, human ISG became the standard treat-
ment for patients with primary antibody deficiencies (PAD) who
develop chronic bacterial infections (9). Preparations in which
antibodies were enriched approximately 10- to 20-fold in 15–
18% solutions were administered intramuscularly, a route, which
caused problems. The intramuscular injection was painful, max-
imum serum levels were not reached before 24 h and could take
several days, and in vivo recovery was usually less than 50% (10).
At higher dosages, the preservative containing mercury caused
increased concern (11). Intravenous administration would clearly
obviate many of these problems but led to severe systemic reactions
in 15–25% of patients. Patients with antibody deficiencies were
particularly susceptible (12). The hypothesis that Ig aggregates
in the preparations were leading to systemic complement acti-
vation (13) led manufacturers to explore ways of removing such
aggregates as a way of preparing an intravenously administered
product. These included digestion with enzymes such as pepsin
and plasmin, leading to Ig fragments, which could bind antigens
and were tolerated intravenously but which were lacking in effector
functions and had very short intravascular lives. Further modifi-
cations involving chemical manipulation with β-Propiolactone,
sulfonation, and alkylation resulted in intact molecules, with loss
or modification of certain functions (14). By the end of the 1970s,
various modifications of the original Cohn procedure resulted in
a number of products containing >99% intact, monomeric Ig,
well-tolerated intravenously, and able to be infused in high vol-
umes and result in a prolonged presence of high Ig levels in the
patient’s blood. Coupled with the increasing range of indications
for Ig in a number of autoimmune and inflammatory diseases, this
ability to delivery higher dosages, and improve clinical outcomes,
in immune deficient patients ushered in the current era of ever
increasing usages of immune globulin therapies.
IMMUNOGLOBULIN THERAPIES – CURRENT PRODUCTS,
CURRENT ISSUES
Bruton first treated agammaglobulinemia in 1952 with ISG
administered subcutaneously (8), a route, which was supplanted
first by intramuscular and, since the 1980s, intravenous, products.
Over the past decade, subcutaneous products have been developed
with an enhanced capacity to allow home care and avoid adverse
events (15). More recently, most manufacturers have acquired
approval to market products for both intravenous and subcuta-
neous routes with increased strengths, with Ig concentrations of
up to 20% compared to the mainstream intravenous products
of 4–5%, as well as faster infusion rates. Most of these devel-
opments have been spurred by economic considerations, aimed
at minimizing time in hospitals (16), while allowing patients
more freedom through home therapy. In addition, reports that
increasing dosages result in a continuing improvement in clinical
outcomes in PID (17) have possibly encouraged the development
of more concentrated solutions. As Ig consumption has continued
to increase, payer influence in therapeutic practice, particularly in
USA, has become a matter of concern (18, 19). Increasingly, the
techniques of mainstream pharmacoeconomics have been used to
question the allocation of health care resources to Ig, although
such analyses have been limited to indications other than PID so
far (20, 21).
HISTORICALLY RECOGNIZED ADVERSE EFFECTS OF Ig
THERAPIES
Ig therapies have been associated with a number of adverse side
effects, which have been extensively reviewed in Ref. (22). The
present work does not intend to reiterate these efforts, which have
all drawn attention to the rarity of serious side effects. Rather,
we intend to focus on effects, which, at one time or another,
increased in frequency as a result of what were, retrospectively,
recognized as ensuing from changes in plasma collection and man-
ufacturing methods. We have chosen three such adverse events:
pathogen transmission, thromboembolism, and hemolysis. Our
aim is to demonstrate how the uniqueness of each manufacturer’s
process influences the product, and reinforces the concept that Ig
therapies, as biological drugs, cannot be viewed as generic and
interchangeable.
PATHOGEN TRANSMISSION ISSUES IN Ig THERAPIES
All plasma protein therapies had a history of transmitting
pathogens before the current era characterized by robust pathogen
elimination steps in the manufacture came into effect. Intramus-
cular Ig products transmitted hepatitis B on rare occasions (23)
but were not associated with the transmission of other blood-
borne viruses. The presence of antibodies to the respective viruses,
which was the basis of the protective action of specific IG prod-
ucts, was assumed to account for the rarity of transmission by ISG.
In addition, the sequential precipitation of fractions during the
Cohn process was thought to partition virus away from the ther-
apeutic Ig fraction (24). Initial experience with early intravenous
preparations seemed to support this safety record.
Over the early 1980s, several IVIG preparations manufactured
at pilot scale transmitted Non A-Non B hepatitis, subsequently
shown to be hepatitis C (HCV). Changes in the finishing steps used
to remove ethanol from the final product were initially ascribed
as the cause of the different infectivity of these IV preparations
compared to their IM counterparts (25), as the Cohn system com-
mon to both products was considered to have a high HCV clearing
capacity (26). This was subsequently shown to be modest in the
absence of a specific virus inactivating step (27). Such steps were
introduced into the manufacture of IVIG from the early 1990s
onward, but not in time to prevent two major outbreaks of HCV
in recipients of intravenous Ig.
HCV FROM ANTI-D – “THE ROAD TO HELL. . .
In 1994, reports emerged of HCV transmission in Irish women,
subsequently linked to the administration of anti-D Ig (28). His-
torically, anti-D Ig is an intramuscular preparation, which, up to
the time of this incident, had a strong safety record. Investigations
showed that the transmissions occurred during 1977 and 1978,
following administration of an anti-D product manufactured on
a small scale in the Irish blood service’s facility in Dublin. The
method used was a chromatographic technique developed in East
Germany some years before (29), and, as in the case of the parent
facility, was introduced in order to maximize the yield of anti-D
from domestic plasma, and achieve self-sufficiency in this product
in the absence of a domestic Cohn fractionation facility (30). Con-
currently, HCV from the original product was also shown to trans-
mit HCV (31). Genomic studies revealed concordance between the
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HCV in the product and that in the infected patients, and the orig-
inal contamination was traced to one infected donor contributing
through plasmapheresis for therapeutic purposes (32).
This epidemic in Irish women affected some 400 recipients of
a product, which has, in its classical form, had an unblemished
safety record (33). A process executed by the Irish government
as a result of this catastrophe led to profound reform in the
blood service and its oversight (34). The Irish Blood Service,
which was relatively unsupervised at the time of these events,
chose, in its quest for self-sufficiency in anti-D, a manufactur-
ing method, which was relatively new and untested through the
long years of experience, which had resulted in high levels of confi-
dence in Cohn fractionated product. Clearly, the chromatographic
method had little capacity to eliminate the viral load resulting
from one repeat plasmapheresis donor. Reliance on the safety
history of anti-D ignored the effect of a total change in manu-
facture, in a modest facility with little adherence to the principles
of good manufacturing practice, and where high-risk donors were
accepted for contribution to the plasma pool. In the sad history of
pathogen transmission through plasma products, it is difficult to
find another accident of such obvious culpability. It also provides
a salutary example of the difficulty in predicting the outcome of
changes in established manufacturing techniques on the safety of
products. It is not the only such example.
THE GAMMAGARD INCIDENT – . . .. . .. . .IS PAVED WITH
GOOD INTENTIONS”
The Irish/German incident involved an intravenous product
administered to healthy women. In 1994, reports emerged indi-
cating an epidemic of HCV in recipients of polyclonal IVIG from
a specific manufacturer. This product – Gammagard from Baxter
Healthcare Corporation – had been licensed in USA since 1986
and had demonstrated a good safety record, including lack of evi-
dence of transmission of Non A, Non B hepatitis (35). Despite this,
an apparent epidemic of HCV occurred in recipients given Gam-
magard over 1993–94 (36). Gammagard – and all other plasma
products – differed in one important feature in 1993 relative to
1986; in the intervening period, the characterization of HCV and
the introduction of rapidly succeeding tests for anti-HCV antibody
resulted in the rapid diminishment of anti-HCV from transfusion
products and the raw material for plasma fractionation. While
this immediately resulted in a substantial increase in the safety
of transfusion products, a concurrent increase in the safety of
pooled plasma products could not be assured. The safety of plasma
products is primarily assured through pathogen elimination pro-
cedures, which enhance safety margins to a much higher extent
than the donor selection and testing measures,which still underpin
the safety of single or small pool transfusion therapies (37).
Scientific opinion at the time of the introduction of the anti-
HCV test included those who speculated that the exclusion of
anti-HCV antibodies from fractionation pools might decrease
product safety (38). The US FDA did not require HCV antibody
testing for source plasma for fractionation until experiments in
their laboratories indicated that the removal of such antibodies
did not affect safety from HCV (39). These experiments used
plasma tested negative with the first-generation anti-HCV test,
which does not exclude all antibody units, particularly units with
HCV antibody specificities against HCV envelope proteins (40).
Other works showed that the Cohn system did not clear HCV
from the final therapeutic fraction (26). After investigating the
Gammagard incident (41), the FDA scientists hypothesized that
the exclusion of anti-HCV antibodies against HCV envelope pro-
teins through the use of second and third generation anti-HCV
tests had affected the portioning of HCV during fractionation, to
result in free, viable virus being deposited in the Ig fraction, which
otherwise would have been neutralized by antibodies to HCV (42,
43). Although the data available make this hypothesis persuasive, it
is regrettable that a specific viral inactivation step, which had been
under development for this product for some years had not been
introduced in time to obviate any viral transmission. The step was
hastily approved by the FDA and introduced in the wake of the
Gammagard incident (36).
This incident continues to accentuate the point made above
that the safety of Ig products cannot be assumed on the basis of
historical experience, when any variation in the complex nexus
of processes, which constitute the manufacture of Ig products is
instituted. In this particular instance, a test, which unquestionably
led to the enhancement of the safety of transfusion products was
insufficiently assessed in its potential role in Ig safety, and was
assumed to contribute to safety in the absence of specific viral
safety measures. The rarity of viral transmission from Ig prod-
ucts was considered to be a good foundation for variations in
their manufacture, in the absence of any scientific validation. The
presumption of linearity in blood safety, i.e., assuming a capac-
ity for predicting the future safety of plasma products on the
basis of past experience, was fulfilled following these incidents
through the efforts of the plasma industry and its regulatory over-
seers in introducing the complex nexus of measures for ensuring
the safety of donors through the exclusion of high-risk groups,
the screening of donations and plasma pools with nucleic acid
tests to minimize the inclusion of donors in the silent “window
period” of infection (44) and the implementation of dedicated
pathogen reduction steps in the manufacture, which ensured that
Ig therapies were safe from established and emerging pathogens.
In particular, the role of pathogen reduction steps in overcom-
ing the “Non-Linearity” of blood safety risks cannot be over-
emphasized (45). Early precautionistic measures implemented by
regulators to minimize exposure to products potentially contam-
inated with prions from patients with transmissible spongiform
encephalopathies (TSEs) led to product recalls and shortages (46).
In the absence of a screening test, these measures could only
be revised with the introduction of steps in the manufacture,
which were shown to decrease prion contamination during plasma
fractionation (47). The absence of infection in a patient who
received Ig manufactured from a donor who subsequently devel-
oped variant Creutzfeldt–Jakob disease (vCJD) demonstrates the
effectiveness of these measures (48).
The salutary experiences encountered during the evolution of
Ig therapies to their current status of safety from blood borne
pathogens, unfortunately, did not prevent similar problems in
other areas as a result of manufacturing changes in succeeding
years, as we shall now review.
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THROMBOEMBOLIC EVENTS
Until recently, thromboembolic sequelae (TEEs) of Ig administra-
tion were relatively rarely reported, although their consequences
were severe. With the increasing level of adverse event monitor-
ing required of plasma therapies, increasing reports of these events
have been published. Given the dramatic and often life threatening
nature of these incidents, the increase in reports may be assumed
to reflect an increased incidence. The interest and concern in this
issue increased considerably when a major product was recalled
from the North American and European markets because of an
increased incidence in thromboembolic events. The product –
Octagam from Octapharma – had a good safety record prior to this
incident (49). The regulatory agencies and the industry collabo-
rated in investigating the putative causes in the increased incidence
of TEEs, including the Octagam problem, with the US FDA hold-
ing a workshop in 2011 whose proceedings are available (50). As
a result of these investigations, the causative agent involved in the
increased thrombogenicity of Ig preparations was determined to
be coagulation Factor XI and XIa, generated in increased amounts
following changes in the manufacturing procedures introduced
over the previous years. The regulatory agencies mandated the
introduction of changes in the manufacturing schemes of prod-
ucts determined to have increased Factor XI (51), and provided
guidance and reference preparations for testing methods for FXIa
in Ig (52). Further guidance was offered subsequently emphasizing
the need to factor in patient characteristics in the administration
of Ig (53), following epidemiological investigation, which showed
that the majority of affected patients had pro-thrombotic co-
morbidities (54). A high level warning on the risk of thrombosis
was mandated for the product information available to patients
and prescribers (55).
These regulatory measures indicated a somewhat belated recog-
nition of the multifactorial nature of the problem of TEEs from
Ig therapies. It appears definite that a previously very rare adverse
event increased in reported incidence in the early 2000s. The attri-
bution of increased FXIa levels in the product as a causal agent
precedes this period (56), as do many of the manufacturing meth-
ods and variations described for the products associated with the
highest TEE incidence (57, 58). These products included Octagam
(Octapharma) and Vivaglobin (CSL), a 5% (for the formula-
tion associated with TEE) intravenous and a 16% subcutaneous
preparation, respectively. The variations in the methods, which
are referred to in the literature describing the TEE incidents are
common measures used by most manufacturers, and must be pre-
sumed, if they were introduced following initial market approval,
to have been incorporated into standard practice following regu-
latory scrutiny and clinical studies. Any such regulatory processes
failed to detect any problems, providing a sober example of the
limitations of mainstream regulation and the difference between
efficacy as assessed by regulators and effectiveness as reflected
from the real world of therapeutic practice (59). Recalls of prod-
uct only occurred for Octagam, despite an FDA investigation in
which interrogation of a large US health insurance claims revealed
higher risks with Vivaglobin (60). These risks were also higher in
European countries but not to the levels reported in USA (61).
Vivaglobin was subjected to scrutiny and warnings (62), and was
withdrawn from the market concurrently with these events to be
replaced with a 20% SCIG – Hizentra (63) – using a process vali-
dated to exclude pro-coagulants (64). The paucity of TEE reports
following these incidents indicates that the measures introduced
led to the desired effects. It would heighten the understanding of
this and similar problems if investigations were to be done and
reported on any changes in clinical and product administrative
practices, such as infusion rates. The continuing increase in con-
sumption of Ig therapies (65) does not indicate any modification
in dosage and other issues, which are considered to play a role in
TEEs (66).
HEMOLYSIS
Like TEE, intravascular hemolysis following Ig administration is a
rare adverse event, which seems to be increasing in frequency (67,
68). A workshop was again convened by the FDA in January 2014
to assess this problem. Transcripts are available (69). Regulatory
laboratories have determined that products with high concentra-
tions of Ig, which are produced by revised versions of the classical
fractionation scheme are preferentially associated with reactions
(70) and are also associated with the highest titers of blood group
antibodies anti-A and anti-B (71). One company obtained reg-
ulatory approval for updates to its safety information regarding
hemolysis, specifying the role of dosage and the relationship to
patient blood group and underlying disease state (72).
Investigations from the industry indicate that the apparent
increase in the incidence of hemolysis may be related, as with TEEs,
to changes in manufacturing methods introduced over recent years
in order to increase the yield of Ig from plasma. Classical Cohn
fractionation has been shown to result in a substantial reduction
in isoagglutinin titer through the sequential removal through pre-
cipitation of Fraction I and, in particular, Fraction III (73, 74), and
modifications of the scheme to omit these sequential precipita-
tions or to purify Ig with different precipitating/chromatographic
techniques result in products with little removal of isoagglutinins.
As a result, manufacturers are assessing the feasibility of intro-
ducing further modifications in the fractionation of the current
generation of products in order to remove isoagglutinins (75),
as well as screening donors to exclude high isoagglutinin titer
donations from the fractionation pool (76).
REFLECTIONS ON RECENT ADVERSE EVENT REPORTS
The past 20 years have seen the following developments in Ig
therapies:
1. The introduction, in common with all plasma protein therapies,
of measures to decrease pathogen transmission.
2. A widening of indications, in particular to treat autoimmune
neuropathies such as Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP), GBS, and MMN.
3. A consequent drive to increase Ig yield from plasma, through
modification of the classic ethanol precipitation scheme or its
abandonment to other techniques.
4. A consequent increase in the cost of treating these disorders,
leading to scrutiny by reimbursement agencies and pressure to
cut costs.
5. The introduction of more concentrated solutions administered
intravenously through high infusion rates, and subcutaneously,
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at least partly fueled by the need to decrease costs through
lessening hospital length of stay periods.
6. The emergence of adverse events at higher incidence than
historically expected.
The contention of this work is that developments 1–5 led to
development 6. We propose this as a “Popperian” hypothesis, able
to be falsified through evidence. We do not assert this with the aim
of ascribing blame, but rather as a route to a better understanding
of Ig therapies and the need to address their benefits as well as their
limitations. We propose the following aspects merit consideration.
THE DIFFICULTY IN PREDICTING OUTCOMES IN BIOLOGICAL
THERAPEUTICS
Murphy has pointed out that a linear approach to predict the
safety of blood-derived therapies is not desirable (77), proposing
that many features of the blood system show characteristics of the
chaotic behavior found in systems composed of complex interde-
pendent components. Reflecting on the myriad of factors, which
may affect the safety and efficacy of a product made, as are Ig ther-
apies, from the blood of tens of thousands of individuals using a
complex manufacturing process, the capacity for apparently minor
and well-intentioned variations in donor composition and tech-
nology to result in deleterious outcomes is not to be wondered at.
Hence, oft-stated claims about “zero risk” plasma therapies and
“well-controlled” manufacturing processes risk being hubristic at
best. Considering the scenarios, which ultimately led to pathogen
transmission from blood in the past 20 years resonate, superfi-
cially, more to science fiction than to what was current empirical
knowledge (78), any hypothesis proposing caution before the
implementation of any potential perturbations in the blood safety
landscape deserves to be treated with respect. Hence, the doubts
shown on the advisability of anti-HCV testing for plasma destined
for Ig production were shown to be justified, and the empiri-
cal evidence supposedly disproving this hypothesis was shown to
be incomplete, unfortunately after affected product transmitted
HCV. Similarly, changes in the manufacturing method intended to
increase yield and lead to“self-sufficiency”resulted in infections in
healthy women given anti-D, a product with an unblemished safety
record when manufactured in the classical fractionation scheme.
Clearly, improving blood transfusion safety through HCV anti-
body testing and improving anti-D access from a domestic source
were well-intentioned policies, which, however, failed to take into
account the specialized and complex area of plasma protein man-
ufacture, with its vulnerability to processing changes. Similarly,
the more recent events whereby adverse events hitherto rare in
incidence became more common following, again, manufacturing
changes whose potential effects on the product were insufficiently
considered to demonstrate a failure by industry and regulators
alike, in not appreciating that the rarity of such events with the
classical products indicated a robustness in the manufacturing
method, long derided as“bucket chemistry,”which the more recent
technologies failed to attain. When Oncley and co-workers had
specifically reported in 1949 that Fraction III in the Cohn sys-
tem contained the bulk of the isoagglutinins (79), was it to be
wondered when omission of this step led to hemolytic sequelae
in patients? We would contend that the evidence for safety of Ig
therapies, before these changes and the subsequent problems, was
evident, and “If it ain’t broke, don’t fix it” might have played a role
in the decision-making process.
THE NEED FOR HIGHER YIELDS
As we have discussed, the driver for changes in the classical tech-
nologies has been the need for higher yields of Ig. Ig yield from the
classical Cohn scheme is of the order of 3 g/L of plasma at best (14).
The current generation of products using modified techniques is
obtained at yields of 3.5–5.4 g/L (14, 80), compared to plasma lev-
els of around 6.5–8.5 g/L in most of the raw material used by the
manufacturers (81). We presume that further enhancements in
yield are possible and that manufacturers will continue to exam-
ine the feasibility of modifications to the fractionation process.
Such modifications generally require regulatory approval, which
may include evidence of clinical efficacy and safety. The failure of
agencies across the world to specify regulatory processes able to
detect the harmful features introduced in previous modifications
such as those discussed in this work does not augur well for the
safety of any further changes.
CLINICAL NEED OF Ig THERAPIES
An analysis of the legitimate clinical need for Ig is legitimate in
order to assess the demand for plasma and ensure optimal care.
An analysis of the mainstay indication – substitution therapy in
patients with humoral immune deficiencies – using published
evidence for the variables currently influencing clinical need deter-
mined a requirement of 72 g per thousand population for this
purpose (82), a need, which exceeds the actual current usage in
most countries. This indication represents around 30% of overall
Ig usage in published sources (83). Around 60% of Ig is used for
immunosuppressive treatment of a number of autoimmune dis-
orders, with particularly large volumes consumed by neuropathies
such as CIDP. Although much is made about the so-called “off-
label” indications of Ig, there is little doubt that, in the established
markets, the vast majority of prescriptions for Ig are for evidence-
based indications. This is indicated by the outcomes in the Aus-
tralian system, where delivery of Ig, through a single government
payer, is conditional to adherence to a set of prescribing guide-
lines, which allocate the product strictly and solely to indications
with the highest level of evidence (84). It is, therefore, likely that,
as diagnosis and therapeutic practice improve, the demand for Ig
will continue the inexorable rise, which has been recorded over the
past 10 years.
It behooves all players in this area to scrutinize such prac-
tice. The increase in Ig consumption is based on the ability to
deliver large doses of product through the intravenous route
and, increasingly, through subcutaneously administered deposits.
More understanding is needed on the optimal dosage regimen for
the different patient groups. In immune deficiency, one hypoth-
esis, fueled by a meta-analysis of clinical trials, proposes that
continuous increases of Ig dosage to higher through levels will
continue to lead to clinical benefit through decreasing pneumo-
nia episodes (17). This hypothesis suggests that patients should
attain Ig through levels to at least the mid-normal range of Ig lev-
els. In contrast, the work of Quinti et al. (85) on a prospectively
studied PID patient cohort found no benefit in the same clinical
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indicator when through levels were above 400 mg/dL. We suggest
that, in an era of advocacy for personalized medicine (86), focusing
on the clinical condition of patients and individualizing therapy
according to such data needs to replace the“guideline”driven prac-
tices, which have underpinned much of therapeutics, including
the treatment of patients with Ig therapies. Milito et al. (87), using
a pharmacokinetic-driven approach, have shown that stratifying
PID patients according to clinical phenotype permits the individ-
ualization of Ig dosage and results in significantly lower total Ig
usage than the standard dosage regimen. While large prospective
multicenter studies are needed to confirm and augment this work,
we suggest that agencies seeking to ensure, for financial reasons,
more “rational” Ig therapy would do well to consider the funding
of such studies if patient care is to be optimized.
The considerable Ig usage, in doses far exceeding those used
in PID, for autoimmune disorders also requires review and more
investigation. The ways in which Ig modulates the immune system
in these diseases is still the subject of research and is probably mul-
tifactorial, but evidence for the role of the Fc portion of Ig appears
compelling (88). Enhancing the sialylation of the Fc portion has
been proposed as a specific route to more targeted Ig therapies
for autoimmune and inflammatory states, allowing more potent
preparations at lower dosages of total Ig (89), and a commer-
cial development, currently lacking in detail, has been announced
(90). Keeping in mind that the majority of the recently encoun-
tered adverse events have affected patients with these disorders,
and that causality has been ascribed to high doses, further work
on the establishment and development of this therapy is a priority
and a challenge for industry and regulators alike.
SUMMARY AND CONCLUSION
Ig therapies are life-saving medicines, which have revolutionized
the treatment of a large number of rare and severe chronic immune
deficiency and autoimmune disorders. Industry investment in the
improvement and administration of these therapies has increased
greatly the number of patients, which can benefit, enhancing life
expectancy and quality of life. This has also led to an increase
in the adverse events associated with these medicines. Current
regulatory constructs are unable to predict such events prior to
the introduction of the therapies on the market place. Hence, an
effort to better understand the manufacture and indications of
these therapies is mandatory. Rather than treating Ig as a form of
“gasoline,” putting more in the patient “tank” in order to get more
clinical “mileage,” personalizing patient care and developing a new
generation of more specific, targeted therapies should be the focus
of the coming years of therapeutics. We suggest that the seeds of
such approaches are appearing, and that more studies will develop
these if sufficiently resourced. We propose that the current era of
financial stringency should not be the excuse for rationing Ig ther-
apies to the detriment of patient care, but should act as the spur
to improving our understanding and use of these crucial natural
molecules.
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